Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Leadership Transition - Cerus Corporation announced the appointment of Vivek Jayaraman as President and Chief Executive Officer, effective July 1, 2026, with William "Obi" Greenman transitioning to Executive Chairman of the Board [1][2] - The leadership change is part of a succession planning process aimed at preparing for the next phase of growth at Cerus [2] Executive Background - Vivek Jayaraman has been with Cerus since 2016, initially as Chief Commercial Officer and then as Chief Operating Officer since 2020, during which he helped grow annual product revenue from less than $40 million to over $200 million by 2025 [2][3] - Obi Greenman has served as CEO for over 15 years, transforming Cerus from a pre-clinical development company into a global commercial enterprise with product sales in over 40 countries [3][4] Future Goals - Vivek Jayaraman expressed his commitment to broadening patient access to the INTERCEPT Blood System globally, expanding leadership in transfusion medicine, and improving patient outcomes [3] - Obi Greenman highlighted the company's achievements, including four FDA product approvals in the past decade and a robust innovation pipeline, positioning Cerus well for future growth [4] Company Overview - Cerus Corporation is dedicated to safeguarding the world's blood supply and aims to become the leading global blood products company, developing technologies and pathogen-protected blood components [8] - The INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma, with ongoing regulatory review for the red blood cell system in Europe [8]